Project Grant R43TR002791

This Cooperative Agreement award, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is funding the development of novel lipid nanoparticles (LNPs) for delivering nucleic acid-based therapeutics to the brain. The total award amount is $843,806.00 and the project period runs from April 10, 2025 to March 31, 2030. The goal of this project is to...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $302,605.00 to Chimerna Therapeutics, Inc. to develop a scalable and low-cost method for semi-synthesis of site-specifically labeled circular RNAs (circRNAs). The goal is to improve the endosomal escape of RNA therapeutics by conjugating circRNAs with lipids to facilitate their delivery and therapeutic effect. The project aims...

The National Institute of General Medical Sciences (NIGMS) awarded a $963,619 Project Grant (CFDA 93.859) to Osem Fluidics Inc. on January 1, 2025 for a project titled "Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery". The project aims to develop 3D-printed microfluidic channel architectures to precisely control the structure and properties of lipid nanoparticles (LNPs) in order to enhance their transfection efficiency...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $1,077,369 to Captis Diagnostics Inc. to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid, efficient isolation of extracellular vesicles (EVs) from non-invasive bodily fluids. The project aims to optimize the LNP technology for EV enrichment from plasma, serum, urine, and saliva, and evaluate, validate, and improve the LNP prototype as a...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid-based therapeutics to the brain for treating Alzheimer's disease (AD). The $835,417 award will support research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, elucidate their trafficking across the blood-brain barrier, engineer siRNA and mRNA sequences to modulate APOE...

This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...

This $457,390 Project Grant award from the National Science Foundation's (NSF) Division of Materials Research aims to develop a new mRNA delivery system based on functional phosphoserine (PS) lipids. The award will support research to understand the targeted and immunomodulatory properties of these zwitterionic functional materials for mRNA delivery, with potential applications in gene therapy, protein-replacement therapy, and cancer immunotherapy. Key objectives include enhancing mRNA...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $299,504 Project Grant to Imetabolic Biopharma Corp on Sep 15, 2024. The grant supports the development of a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) from circulation. The research aims to reengineer an APOC-III antagonist, IMBP-001, to include bioactive APOE mimetic peptides. This dual-domain therapeutic candidate can bind to...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $365,616 to Gettysburg College to develop a library of novel triazine-based, ionizable lipids for use in lipid nanoparticle (LNP) formulations to deliver RNA into cells. The key objectives are to investigate how modifications to the lipid head groups and hydrophobic tails affect LNP physical properties and in vitro biological activity...

This federal Project Grant award, valued at $419,398, was provided by the National Center for Advancing Translational Sciences (NCATS) under the CFDA Program 93.350 to accelerate the translation of oligonucleotide therapeutics by enhancing delivery. The project aims to develop a small molecule solution to improve the delivery of systemically administered oligonucleotide therapeutics to extrahepatic tissues, a critical unmet need that has limited the broad clinical translation of these...